Alembic Pharmaceuticals Limited

APLLTD

INE901L01018

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:46 2024-04-26 am EDT			5-day change	1st Jan Change
990.2 ^INR	-0.73%		+5.53%	+30.40%

Apr. 18	Alembic Pharmaceuticals Board to Consider Dividend for Fiscal 2024; Shares Drop 3%	MT
Apr. 08	Alembic Pharmaceuticals Limited Received 3 Assessment Orders from the Office of Assistant Commissioner (ST), Andhra Pradesh	CI

Alembic Pharmaceuticals Limited Announces Disruption of Manufacturing Operations at Namthang, South Sikkim

October 04, 2023 at 03:41 am EDT

Alembic Pharmaceuticals Limited informed that due to flash floods in river Teesta because of cloud burst, water entered its manufacturing facility at Namthang, South Sikkim and hence manufacturing operations stand disrupted with effect from 4 October, 2023.

Latest news about Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Board to Consider Dividend for Fiscal 2024; Shares Drop 3%	Apr. 18	MT
Alembic Pharmaceuticals Limited Received 3 Assessment Orders from the Office of Assistant Commissioner (ST), Andhra Pradesh	Apr. 08	CI
Alembic Pharmaceuticals Appoints Manish Kejriwal as Independent Director	Apr. 02	CI
Alembic Pharmaceuticals Gets US FDA Tentative Nod for Generic Breast Cancer Treatment	Apr. 02	MT
Alembic Pharmaceuticals Limited Receives One US Food & Drug Administration Product Approval	Apr. 01	CI
Alembic Pharmaceuticals Limited Announces Board Cessations	Apr. 01	CI
Alembic Pharmaceuticals Limited Receives Order from Commission of Customs, Mumbai Zone- III	Mar. 18	CI
Alembic Pharmaceuticals' Oncology Plant in Gujarat, India Gets One Observation from US FDA	Mar. 11	MT
Alembic Pharmaceuticals Limited Announces United States Food and Drug Administration Conducted an Inspection At Oncology Formulation Facility At Panelav	Mar. 08	CI
Crisil Keeps AA+ Rating on Alembic Pharmaceuticals' Bank Loans with Stable Outlook	Mar. 08	MT
Indian shares seen muted tracking broader Asian equities	Feb. 25	RE
Alembic Pharmaceuticals Fully Resumes Operations at Manufacturing Unit in South Sikkim, India	Feb. 23	MT
Alembic Pharmaceuticals' Consolidated Net Profit Jumps in Fiscal Q3; EPS Tops Estimates	Feb. 06	MT
Alembic Pharmaceuticals' Consolidated Profit Climbs in Fiscal Q3, EPS Beats Estimates	Feb. 06	MT
Transcript : Alembic Pharmaceuticals Limited, Q3 2024 Earnings Call, Feb 05, 2024	Feb. 05
India's Alembic Pharma beats Q3 profit view on strong domestic, US sales	Feb. 05	RE
Alembic Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 05	CI
Alembic Pharmaceuticals Limited Announces Designation of Manuj Desai as Head - It as Senior Management Personnel	Feb. 05	CI
Alembic Pharmaceuticals Expects Operations at Sikkim, India Units to Be Restores in Two Months	Jan. 05	MT
Alembic Pharmaceuticals Extends Corporate Guarantee to US-Based Arm to Secure Credit	Jan. 02	MT
Alembic Pharmaceuticals Receives Various Us Food & Drug Administration Product Approvals	Jan. 01	CI
Alembic Pharmaceuticals Limited Cessation of Mr. Prerepa Sreenivasa Rao as Senior Management Personnel	Jan. 01	CI
Alembic Pharmaceuticals Limited Appoints Pradeep Chakravarty as Head - Global Quality	Dec. 04	CI
Alembic Pharmaceuticals Limited Announces Management Changes	Nov. 27	CI
Alembic Pharmaceuticals Logs Slightly Higher Consolidated Profit in Fiscal Q2; EPS Misses Estimates	Nov. 08	MT

Chart Alembic Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients (API). It delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopaedic and Gynaecology. Products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. It has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its India Formulations. Its subsidiaries include Alembic Pharmaceuticals Inc., Alembic Global Holding SA and others.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Alembic Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

990.2 INR

Average target price

937.7 INR

Spread / Average Target

-5.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ALEMBIC PHARMACEUTICALS LIMITED	+30.40%	2.33B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals